SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Addiction Medicine Consultation — Billie Holiday

PatientBillie Holiday
Date of birth1993-04-07
IdentifiersMRN HR-ML010-SYN; SSN (made up) 000-10-4472
Document date2026-04-27
AuthorJulian Ortiz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Severe opioid use disorder and moderate alcohol use disorder in a 33-year-old singer, five weeks after release from about ten months in custody, when her tolerance is low and her overdose risk high. Buprenorphine with naloxone was started today. Please confirm the medication plan and dose, advise on a medicine for her drinking that is safe with buprenorphine, and help set the monitoring and recovery plan. [S]

Urgency: Within one week, on the same day as her one-week primary care visit. [S]

Questions for the consultant:

History of Present Illness

Ms. Holiday, a 33-year-old singer, is seen at the request of Dr. Mayfield one week after starting buprenorphine with naloxone. She has taken every dose, 4 mg on the first day and 8 mg since, and has used no opioids. She has had no withdrawal, but cravings return each evening, especially after shows. She drinks four or five drinks on performance nights to calm her nerves. She has no history of withdrawal seizures or delirium. She sought treatment for heroin use years ago and says she wants to stay off it and keep singing. Her biggest fear is overdosing now that her tolerance is low. She tours often and worries about getting prescriptions filled on the road. She asked that this note be shared only with Dr. Mayfield. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue dailyOne film under the tongue daily after a 4 mg first doseSublingual route2026-04-20 to 2026-04-27completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once dailyTwo films under the tongue once dailySublingual route2026-04-27activeS
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no responseNasal route2026-04-20activeS
Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route2026-04-27activeS
Thiamine 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-10-19completedS

Problems

ProblemClinical statusVerificationCodeProvenance
Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin useactiveconfirmed F11.20S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use.
Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's deathactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode.

Physical Exam

Vital signs recorded on 2026-04-27; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralAlert and engaged; blood pressure 122/78, pulse 78
EyesPupils normal in size; no tearing
SkinNo injection-site changes or abscesses
NeurologicalNo tremor
PsychiatricCalm and direct; no signs of intoxication or withdrawal

Assessment

Data reviewed: Dr. Mayfield's intake note with the safety assessment, AUDIT-C, DAST-10, and PHQ-9. Last week's results: AST 52, ALT 38, GGT 84 U/L; albumin 4.0 g/dL; bilirubin 0.7 mg/dL; MCV 101 fL; platelets 236; creatinine 0.72 mg/dL; PEth 312 ng/mL; hepatitis C antibody nonreactive (0.09); hepatitis B surface antigen and core antibody nonreactive, surface antibody 3 mIU/mL; HIV antigen-antibody nonreactive. Today's urine drug test: buprenorphine and norbuprenorphine only. Prescription drug monitoring program: no other controlled-substance prescriptions. [S]

Plan of Treatment